Healthcare

As the Healthcare sector emerges from a time of immense pressure and high visibility, we see huge investment, potential and opportunity ahead

Truly dynamic and innovative at its core, Healthcare is poised for a period of growth and transformation. Driven by a range of factors – including Covid-19; greater emphasis on personalisation; digitisation and technological innovation; changing demographics; and shifting customer and patient expectations – organisations of all sizes and ownership structures seek the right leaders to seize this opportunity.

Supporting clients at Board, Executive Committee and leadership levels, we combine extensive experience in and a deep understanding of the wide and varied Healthcare sector, including its clinical leadership, as well as access to relevant talent pools in adjacent consumer-facing industries.

View current opportunities

The MBS Group acts as an advisor to NHS and other public sector bodies on senior appointments. To view current appointments, click here.

Our Experience

Clinical Services

Life Sciences
HealthTech & Digital Healthcare
Insurers
Healthcare Systems
Medical Devices & Diagnostics

Selected Clients

Latest MBS News & Intelligence

IntraHealth returns to profit. The primary care provider, which operates ten NHS GP practices in the north east of England has returned to profit despite continued challenges. It reported losses in 2023 following shortages of doctors, nurses and pharmacists, intensifying cost pressures.
Robeauté raises £23m for neurosurgical robots. The French medtech startup has raised the money to develop microrobots which enter the brain to diagnose, treat and monitor neurological conditions. The robots are the size of a grain of rice and Robeauté will begin human trials in 2026.
Eli Lilly projects strong sales despite missing diabetes medicine targets. The Indianapolis-based pharmaceutical company announced a projection of between $58bn and $61bn in sales over the coming year despite missing its sales targets for diabetes drug, Mounjaro and anti-obesity medicine Zepbound.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.